Updated:
Radius Health
Radius Health is a Boston-based commercial biopharmaceutical company focused on bone health, known for launching TYMLOS and licensing BINOSTO.
Radius Health
Radius Health is a Boston-based biopharmaceutical company whose mission centers on bone health and related therapeutic areas. It launched its first commercial product, TYMLOS (abaloparatide) injection, in the U.S. in 2017, and received supplemental FDA approval to expand TYMLOS in 2022. The company's wealth origin is not publicly tied to a specific family; it operates as a publicly disclosed entity rather than a family office. The company's strategy has centered on bone health product development and commercialization. Its portfolio includes TYMLOS and, following a 2023 exclusive licensing of U.S. rights, BINOSTO (alendronate sodium). Radius' asset-class mix includes pharmaceutical product development and licensing deals. The company's geographic footprint is U.S.-focused, with headquarters in Boston, Massachusetts. Radius Health's team size and total deployment are not publicly disclosed. The company maintains a single headquarters in Boston with no reported additional offices. Its adjacent vehicles include a Medical Support Line and patient-caregiver resources. In 2023, the company licensed U.S. rights to BINOSTO, expanding its bone health business (per the firm, 2023). As of 2024, Radius reports it is growing and seeking additional partnership opportunities. What distinguishes Radius Health structurally is its stated entrepreneurial, growth-minded approach combined with a narrow focus on bone health — a therapeutic area with underserved global populations. The company has not disclosed a succession or governance structure typical of family offices, instead operating as a biopharmaceutical firm with publicly stated values emphasizing agility, integrity, and patient focus.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Boston
Corporate office
22 Boston Wharf Road 7th Floor, Boston, MA 02210, United States
Sector focus
Frequently asked questions
Who runs investment decisions at Radius Health?
Radius Health does not publicly disclose a single named investment decision-maker. As a biopharmaceutical company, its strategy is directed by its executive leadership and board, but specific names and roles are not available on its public channels (per firm website).
How does Radius Health source proprietary opportunities?
Radius Health sources opportunities through licensing agreements and product development in bone health. The 2023 licensing of U.S. rights to BINOSTO is an example of its partnership-based sourcing model (per the firm, 2023).
Is Radius Health structured as a family office or a biopharmaceutical firm?
Radius Health operates as a commercial-stage biopharmaceutical company, not a family office. It does not disclose any family-office structure or wealth origin tied to a specific family (per firm website).
Does Radius Health participate in fund commitments or only direct product development?
Radius Health focuses on direct product development and commercialization rather than fund commitments. Its activities include launching TYMLOS and licensing BINOSTO, both direct operational moves (per the firm).
What investment stages does Radius Health typically target?
Radius Health targets late-stage and commercial-stage pharmaceutical assets. Its products TYMLOS and BINOSTO are both approved and marketed in the U.S., indicating a focus on post-approval expansion (per the firm).
Which sectors does Radius Health explicitly avoid?
Radius Health has not publicly stated sectors it avoids. Its known focus is exclusively bone health and related therapeutic areas, with no disclosed activity in other therapeutic fields (per firm website).
Does Radius Health maintain philanthropic structures, and how are they separated?
Radius Health does not publicly disclose any philanthropic foundations or separate charitable structures. Its corporate mission emphasizes patient care, but no specific foundation is mentioned (per firm website).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: